ArticleThrombosis2011
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.
Article in Thrombosis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Exploring the effects of tinzaparin and cisplatin on lung cancer cells in vitro.Cancer cell international · 2026Article
- Cancer-associated venous thromboembolism: a comprehensive review.Thrombosis journal · 2025Review
- Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment.Biomolecules · 2022Review
- Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.Pharmacotherapy · 2020Review
- Compound Opening Arrow Mixture exerts anti-tumor effects in a mouse model of breast cancer.Scientific reports · 2020Article
- Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.Journal of thrombosis and thrombolysis · 2019Article
- Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour.Case reports in vascular medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH) approximately two decades ago (in contrast to unfractionated heparin and vitamin K antagonists) has provided a class of agents with a favorable therapeutic index. In the review to follow, the literature regarding the use of LMWH in oncologic patient populations is summarized. Topics addressed include prophylaxis, and treatment as well as consideration of the potential anti-neoplastic properties of this class of drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.